Literature DB >> 30419710

[Advances on antimicrobial resistance research of Salmonella enterica Serovar Indiana].

Y J Hu1, Y Y He, J Xu.   

Abstract

Salmonella enterica Serovar Indiana is a common serotype of Salmonella isolated from food especially from poultry meat. Recently it demonstrated a raising tendency of infection cases and isolate numbers with high antimicrobial resistant rate against many common antimicrobials, including quinolones and cephalosporin which were regarded as the first line drug for the treatment of Salmonella infections, and this kind of Salmonella serotype was always carrying complex resistance mechanisms and also a variety of mobile elements, all of these features made the very clinical infections caused by Salmonella hard to treat and brought great difficulties and risks. Here, we review the prevalence of Samonella Indiana on national and international view, and we also anticipate the research progress on antimicrobial drug classes, multi drug resistance, co-resistance and resistance mechanism. We discuss the resistant genotypes, phenotypes, mechanism and transmission of Salmonella Indiana strains isolated from different origins. By introducing the resistance of Salmonella Indiana, we want to attract people's attention to this bacteria and its hazard, and offer some idea to evaluate and treat infections in clinical.

Entities:  

Keywords:  Drug resistance; Multi drug resistance; Resistance mechanism; Salmonella enterica serovar Indiana

Mesh:

Substances:

Year:  2018        PMID: 30419710     DOI: 10.3760/cma.j.issn.0253-9624.2018.11.021

Source DB:  PubMed          Journal:  Zhonghua Yu Fang Yi Xue Za Zhi        ISSN: 0253-9624


  1 in total

1.  Antimicrobial resistance of Salmonella Indiana from retail chickens in China and emergence of an mcr-1-harboring isolate with concurrent resistance to ciprofloxacin, cefotaxime, and colistin.

Authors:  Yujie Hu; Yingying He; Scott V Nguyen; Chang Liu; Chang Liu; Xin Gan; Wei Wang; Yinping Dong; Jin Xu; Fengqin Li; Séamus Fanning
Journal:  Front Microbiol       Date:  2022-09-08       Impact factor: 6.064

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.